Concepts (168)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Non-alcoholic Fatty Liver Disease | 6 | 2024 | 61 | 1.750 |
Why?
|
| Liver Neoplasms | 11 | 2024 | 164 | 1.580 |
Why?
|
| Carcinoma, Hepatocellular | 10 | 2024 | 130 | 1.320 |
Why?
|
| Liver Transplantation | 4 | 2024 | 51 | 1.190 |
Why?
|
| Hepatitis C | 2 | 2022 | 38 | 0.940 |
Why?
|
| Hepatopulmonary Syndrome | 1 | 2021 | 3 | 0.770 |
Why?
|
| Disease Progression | 4 | 2021 | 450 | 0.690 |
Why?
|
| Liver Cirrhosis | 4 | 2024 | 67 | 0.580 |
Why?
|
| Liver | 2 | 2019 | 415 | 0.490 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 1394 | 0.440 |
Why?
|
| Bile Duct Neoplasms | 1 | 2011 | 3 | 0.380 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2011 | 3 | 0.380 |
Why?
|
| Cholangitis | 1 | 2011 | 2 | 0.380 |
Why?
|
| Cholangiocarcinoma | 1 | 2011 | 5 | 0.380 |
Why?
|
| Immunoglobulin G | 1 | 2011 | 266 | 0.330 |
Why?
|
| Sulfotransferases | 4 | 2016 | 8 | 0.330 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2009 | 27 | 0.320 |
Why?
|
| Hepatitis B, Chronic | 2 | 2022 | 6 | 0.310 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2009 | 104 | 0.300 |
Why?
|
| Neoplasm Proteins | 1 | 2009 | 122 | 0.300 |
Why?
|
| Hepatitis C, Chronic | 2 | 2022 | 30 | 0.300 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2009 | 143 | 0.300 |
Why?
|
| Humans | 18 | 2024 | 26829 | 0.270 |
Why?
|
| Sulfatases | 3 | 2020 | 6 | 0.230 |
Why?
|
| Antineoplastic Agents | 1 | 2009 | 657 | 0.210 |
Why?
|
| Databases, Factual | 1 | 2024 | 250 | 0.210 |
Why?
|
| Hepatitis B | 1 | 2022 | 12 | 0.210 |
Why?
|
| Neovascularization, Pathologic | 2 | 2016 | 144 | 0.200 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2024 | 276 | 0.190 |
Why?
|
| Allografts | 1 | 2021 | 11 | 0.190 |
Why?
|
| Telomere | 1 | 2021 | 28 | 0.190 |
Why?
|
| Bone Marrow Transplantation | 1 | 2021 | 42 | 0.190 |
Why?
|
| Lipase | 1 | 2021 | 10 | 0.190 |
Why?
|
| MicroRNAs | 1 | 2024 | 280 | 0.180 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2020 | 4 | 0.170 |
Why?
|
| Emigrants and Immigrants | 1 | 2020 | 18 | 0.170 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2020 | 4 | 0.170 |
Why?
|
| Inflammation | 1 | 2024 | 601 | 0.170 |
Why?
|
| Fibrosis | 2 | 2018 | 115 | 0.170 |
Why?
|
| Male | 11 | 2024 | 12870 | 0.170 |
Why?
|
| STAT3 Transcription Factor | 1 | 2020 | 85 | 0.170 |
Why?
|
| Animals | 8 | 2021 | 9963 | 0.160 |
Why?
|
| Liver Neoplasms, Experimental | 2 | 2009 | 27 | 0.160 |
Why?
|
| Smad Proteins | 2 | 2016 | 18 | 0.160 |
Why?
|
| Risk Factors | 3 | 2024 | 2011 | 0.150 |
Why?
|
| Collagen | 1 | 2018 | 147 | 0.140 |
Why?
|
| Mice | 7 | 2021 | 4408 | 0.140 |
Why?
|
| Membrane Proteins | 1 | 2021 | 465 | 0.140 |
Why?
|
| Thiazolidinediones | 1 | 2017 | 10 | 0.140 |
Why?
|
| Vitamin E | 1 | 2017 | 11 | 0.140 |
Why?
|
| Aged | 5 | 2024 | 5167 | 0.130 |
Why?
|
| Cell Adhesion Molecules | 1 | 2016 | 64 | 0.130 |
Why?
|
| Hypoglycemic Agents | 1 | 2017 | 105 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2016 | 444 | 0.130 |
Why?
|
| Female | 8 | 2024 | 14463 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 357 | 0.120 |
Why?
|
| Diet | 1 | 2017 | 223 | 0.120 |
Why?
|
| Middle Aged | 5 | 2024 | 6818 | 0.120 |
Why?
|
| Minnesota | 3 | 2022 | 41 | 0.120 |
Why?
|
| Transforming Growth Factor beta | 1 | 2015 | 77 | 0.110 |
Why?
|
| Mice, Transgenic | 2 | 2020 | 486 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 309 | 0.100 |
Why?
|
| Exercise | 1 | 2017 | 451 | 0.100 |
Why?
|
| Carcinogenesis | 2 | 2024 | 76 | 0.100 |
Why?
|
| CA-19-9 Antigen | 1 | 2011 | 7 | 0.100 |
Why?
|
| Signal Transduction | 3 | 2016 | 1344 | 0.090 |
Why?
|
| Diagnosis, Differential | 1 | 2011 | 367 | 0.090 |
Why?
|
| Niacinamide | 1 | 2009 | 12 | 0.080 |
Why?
|
| Benzenesulfonates | 1 | 2009 | 18 | 0.080 |
Why?
|
| Phenylurea Compounds | 1 | 2009 | 16 | 0.080 |
Why?
|
| Embryonic Development | 1 | 2009 | 21 | 0.080 |
Why?
|
| Peptides, Cyclic | 1 | 2009 | 30 | 0.080 |
Why?
|
| Transcriptome | 2 | 2021 | 198 | 0.080 |
Why?
|
| Doxorubicin | 1 | 2009 | 74 | 0.080 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2009 | 95 | 0.080 |
Why?
|
| Drug Design | 1 | 2009 | 62 | 0.080 |
Why?
|
| Somalia | 2 | 2022 | 4 | 0.080 |
Why?
|
| Adult | 3 | 2024 | 7383 | 0.080 |
Why?
|
| Pyridines | 1 | 2009 | 99 | 0.080 |
Why?
|
| Neovascularization, Physiologic | 1 | 2009 | 123 | 0.070 |
Why?
|
| Biomarkers, Tumor | 2 | 2024 | 377 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 205 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 216 | 0.070 |
Why?
|
| United States | 2 | 2024 | 2033 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 445 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2019 | 858 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2020 | 390 | 0.060 |
Why?
|
| Liver Diseases | 1 | 2024 | 51 | 0.060 |
Why?
|
| Biomarkers | 2 | 2018 | 733 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2024 | 263 | 0.050 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2022 | 1 | 0.050 |
Why?
|
| Hepatitis B Antibodies | 1 | 2022 | 2 | 0.050 |
Why?
|
| Hepatitis B virus | 1 | 2022 | 16 | 0.050 |
Why?
|
| Hepacivirus | 1 | 2022 | 46 | 0.050 |
Why?
|
| Hepatic Stellate Cells | 1 | 2021 | 14 | 0.050 |
Why?
|
| Hep G2 Cells | 1 | 2021 | 28 | 0.050 |
Why?
|
| Diet, Western | 1 | 2021 | 19 | 0.050 |
Why?
|
| Prevalence | 1 | 2022 | 472 | 0.050 |
Why?
|
| Incidence | 1 | 2022 | 545 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 322 | 0.040 |
Why?
|
| Hepatocytes | 1 | 2021 | 68 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2021 | 163 | 0.040 |
Why?
|
| STAT Transcription Factors | 1 | 2020 | 2 | 0.040 |
Why?
|
| Kenya | 1 | 2020 | 31 | 0.040 |
Why?
|
| Diet, High-Fat | 1 | 2021 | 130 | 0.040 |
Why?
|
| Community-Based Participatory Research | 1 | 2020 | 32 | 0.040 |
Why?
|
| Histology | 1 | 2019 | 7 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2020 | 113 | 0.040 |
Why?
|
| Gene Expression | 1 | 2021 | 406 | 0.040 |
Why?
|
| Transfection | 2 | 2010 | 313 | 0.040 |
Why?
|
| Mice, Nude | 2 | 2010 | 313 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2022 | 1217 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2020 | 172 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2020 | 330 | 0.040 |
Why?
|
| Protein Binding | 1 | 2020 | 632 | 0.040 |
Why?
|
| Biopsy | 1 | 2018 | 199 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 439 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 279 | 0.040 |
Why?
|
| Proteins | 1 | 2019 | 244 | 0.040 |
Why?
|
| Mutation | 1 | 2021 | 817 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 400 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2015 | 2433 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 28 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 129 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 189 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 131 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 1476 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 190 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 253 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2016 | 60 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2010 | 1259 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 453 | 0.030 |
Why?
|
| Plant Lectins | 1 | 2015 | 1 | 0.030 |
Why?
|
| Prothrombin | 1 | 2015 | 15 | 0.030 |
Why?
|
| Protein Precursors | 1 | 2015 | 11 | 0.030 |
Why?
|
| alpha-Fetoproteins | 1 | 2015 | 18 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 910 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2016 | 503 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2015 | 86 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 213 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2016 | 783 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 464 | 0.030 |
Why?
|
| Age Distribution | 1 | 2012 | 70 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2012 | 76 | 0.020 |
Why?
|
| Wnt3 Protein | 1 | 2010 | 3 | 0.020 |
Why?
|
| Glypicans | 1 | 2010 | 3 | 0.020 |
Why?
|
| Wnt3A Protein | 1 | 2010 | 6 | 0.020 |
Why?
|
| Comorbidity | 1 | 2012 | 252 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2010 | 23 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2010 | 56 | 0.020 |
Why?
|
| Luciferases | 1 | 2010 | 49 | 0.020 |
Why?
|
| Wnt Proteins | 1 | 2010 | 32 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2010 | 87 | 0.020 |
Why?
|
| Plasmids | 1 | 2010 | 122 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2010 | 262 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 282 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2009 | 60 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2009 | 88 | 0.020 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2009 | 26 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2009 | 100 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2009 | 31 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2009 | 93 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2009 | 147 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2009 | 247 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 408 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 586 | 0.020 |
Why?
|
| Apoptosis | 1 | 2009 | 739 | 0.020 |
Why?
|
| Young Adult | 1 | 2012 | 2581 | 0.010 |
Why?
|